Shareholders of Galderma Group AG are offering a 6.3% stake in the Swiss skincare group. Buyout group EQT AB, the Abu Dhabi Investment Authority and Auba Investment Pte. Ltd. are looking to sell ...

L'Oréal's return to Galderma suggests it is moving its focus away from traditional cosmetics towards more cutting-edge beauty technology. The Swiss firm offers a broad portfolio of dermo ...

Galderma CEO, Flemming Ornskov said he intends to talk to US retailers about the trade tariffs slapped on imported goods by ...

Galderma will present new data from across its portfolio, including findings from the RELAX and EXPRESSION studies on Relfydess® (RelabotulinumtoxinA ...

The brand benefits from the growing demand for science-based skincare products. In therapeutic dermatology (19% of 2023 net sales), Galderma is a market leader in acne, rosacea, and actinic keratosis.

Galderma will present updates from across its ... two oral presentations – with updates on a number of its innovative products, including Nemluvio, Sculptra, Restylane and Relfydess.

While it might seem a bit “overkill” that Galderma would be using its products in gaming form to help showcase the “dangers of acne and zits,” do you remember what it was like when those ...

as the French firm seeks a cut of the profits from the booming injectable cosmetics market. August 5, 2024 L'Oreal acquires 10% stake in dermatology company Galderma L'Oreal has announced the ...

Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community ...